A new proviso has been inserted in Rule 2 (1)(e), to provided that any Company engaged in Research & Development (‘R&D’) activity of new vaccine, drugs and medical devices in their normal course of business may undertake R&D activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 subject to the conditions that
(i) Such R&D activities shall be carried out in collaboration with any of the institutes or organisations mentioned in item (ix) of Schedule VII to the Act; and
(ii) Details of such activity shall be disclosed separately in the Annual Report on CSR included in the Board’s Report.
Further, in Rule 4(1) the words, excluding activities undertaken in pursuance of its normal course of business have been deleted

 

Effective date: August 24, 2020

 

Source: Companies (Corporate Social Responsibility Policy) Amendment Rules, 2020 dated August 24, 2020


QUICK LINKS

Company or LLP master data

Check Annual Filing Status

Check Company or LLP name

Enquire DIN Status

Associate DSC

Employee login


OUR SERVICES

Incorporation Registration

Company Law Compliance
Board Governance
Health Check Audit

Co-Source 

Corporate Governance
Insolvency and Bankruptcy
Startup
Restructuring
Others

Company Profile

Head Office:  604-605, PP City Center, Road Number 44, Pitampura, New Delhi-110034
Email: info@apacandassociates.com | Tel : +91-11-49058720-21